BTIG Research Issues Pessimistic Forecast for IQVIA (NYSE:IQV) Stock Price

IQVIA (NYSE:IQV - Free Report) had its target price decreased by BTIG Research from $290.00 to $260.00 in a report published on Friday morning, Benzinga reports. BTIG Research currently has a buy rating on the medical research company's stock.

Several other research analysts have also commented on the company. Evercore ISI cut their price objective on IQVIA from $270.00 to $265.00 and set an "outperform" rating for the company in a report on Tuesday, October 8th. Barclays decreased their price target on shares of IQVIA from $260.00 to $255.00 and set an "overweight" rating on the stock in a report on Friday. Deutsche Bank Aktiengesellschaft dropped their price objective on shares of IQVIA from $270.00 to $265.00 and set a "buy" rating for the company in a report on Friday. Morgan Stanley raised their price target on IQVIA from $270.00 to $280.00 and gave the company an "overweight" rating in a research report on Tuesday, July 23rd. Finally, StockNews.com upgraded IQVIA from a "hold" rating to a "buy" rating in a report on Wednesday. Four equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, IQVIA presently has an average rating of "Moderate Buy" and an average target price of $261.24.

IQVIA Price Performance

Shares of IQV stock traded up $3.34 on Friday, reaching $209.16. The company's stock had a trading volume of 1,461,103 shares, compared to its average volume of 1,087,412. IQVIA has a 12-month low of $181.03 and a 12-month high of $261.73. The stock's 50 day simple moving average is $234.31 and its 200-day simple moving average is $229.74. The company has a quick ratio of 0.85, a current ratio of 0.85 and a debt-to-equity ratio of 1.80. The company has a market capitalization of $38.13 billion, a P/E ratio of 27.16, a PEG ratio of 2.11 and a beta of 1.49.

Insider Activity at IQVIA

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the company's stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the transaction, the insider now owns 19,536 shares in the company, valued at approximately $4,812,302.88. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.60% of the stock is currently owned by company insiders.

Institutional Trading of IQVIA

Hedge funds have recently made changes to their positions in the stock. Capital Performance Advisors LLP bought a new position in IQVIA in the 3rd quarter worth about $27,000. Park Place Capital Corp purchased a new stake in shares of IQVIA during the third quarter valued at approximately $28,000. Versant Capital Management Inc increased its position in shares of IQVIA by 733.3% during the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company's stock valued at $26,000 after acquiring an additional 110 shares in the last quarter. Opal Wealth Advisors LLC purchased a new position in IQVIA in the 2nd quarter worth approximately $27,000. Finally, Itau Unibanco Holding S.A. bought a new position in IQVIA in the 2nd quarter valued at approximately $29,000. 89.62% of the stock is owned by institutional investors.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.